Carbidopa: Side Effects, Uses & Monitoring
Carbidopa and levodopa extended release tablets are indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may
- Data source
- FDA labeling via NIH DailyMed (label abff005f…)
- Label version
- current
- Last reviewed
- 2026
Reported adverse reactions
Reactions listed in current FDA labeling, with the highest frequency reported across summarized placebo-controlled trials.
| Adverse reaction (as reported in labeling) | Reported frequency* |
|---|---|
| Dyskinesia | 16.5% |
| Nausea | 5.7% |
| Hallucinations | 3.9% |
| Confusion | 3.7% |
| Dizziness | 2.9% |
| Urinary tract infection | 2.3% |
| Depression | 2.2% |
| Headache | 2% |
| Vomiting | 1.9% |
| Dream abnormalities | 1.8% |
| Dystonia | 1.8% |
| Upper respiratory infection | 1.8% |
| Dyspnea | 1.6% |
| “on-off” phenomena | 1.6% |
| Back pain | 1.6% |
| Constipation | 1.5% |
| Dry mouth | 1.4% |
| Anorexia | 1.2% |
| Diarrhea | 1.2% |
| Insomnia | 1.2% |
*Highest percentage reported for the active moiety across placebo-controlled trial tables in current FDA labeling. Values reflect trial reporting, not your individual risk.
Labeled uses (from FDA prescribing information)
Carbidopa and levodopa extended release tablets are indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.
Conditions associated with Carbidopa in labeling
Frequently Asked Questions
What is Carbidopa used for?
FDA labeling lists the approved uses shown above under "Labeled uses." This summary is informational; only a qualified prescriber can determine whether a medication is appropriate for you.
What are the most commonly reported side effects of Carbidopa?
The table above shows adverse reactions and the highest frequencies reported in placebo-controlled trials summarized in current FDA labeling for Carbidopa. Individual risk varies.
Does Carbidopa require lab monitoring?
Monitoring needs vary. Ask your healthcare provider whether any lab tests apply while taking Carbidopa.
Where does this information come from?
All clinical facts on this page were extracted from the current FDA-registered product labeling for this ingredient, published by manufacturers through NIH DailyMed. See the source link below.
Medical disclaimer: Educational content extracted from public FDA labeling. Not medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.